China
Africa
Explore chapters and articles related to this topic
Treatment of Chronic Fatigue Syndrome
Published in Jay A. Goldstein, Chronic Fatigue Syndromes, 2020
Low-dose oral alpha interferon produces mild to moderate symptomatic improvement in some patients. Oral interferon in a dose of 200 units is now distributed in the form of a tablet which is held in the mouth until it dissolves. Interferon in such a low dose could interact with receptors in the oropharynx which connect to the limbic system and may even be directly transported there.38 Oral alpha interferon is unlikely to directly activate antiviral systems in infected cells. Some clinicians believe that Kutapressin and low dose oral alpha interferon have a synergistic effect.
Herbs with Antidepressant Effects
Published in Scott Mendelson, Herbal Treatment of Major Depression, 2019
Astragalus membranaceus has been found to affect various immunosuppressive treatments. For example, it can enhance the inhibitory effect of corticosteroids on apoptosis.22 It has also been found to enhance the effects of alpha-interferon in human subjects.23 On the other hand, it has also been reported to dampen the immunosuppressive effects of cyclophosphamide.24
Gastrointestinal cancer
Published in Michael JG Farthing, Anne B Ballinger, Drug Therapy for Gastrointestinal and Liver Diseases, 2019
Justin S Waters, David Cunningham
Cancers of the biliary tract, including carcinoma of the gall bladder and cholangiocarcinoma, are rare, and few clinical trials have addressed their management. Patients frequently present with advanced disease that is not amenable to surgical resection, and the prognosis is poor, with a median survival of less than 6 months. Palliative chemotherapy may have a role, as suggested by a trial comparing 5-fluorouracil, leucovorin and etoposide with best supportive care alone. This demonstrated improved survival (6 versus 2.5 months; p < 0.01) and quality of life in the chemotherapy arm.40 This trial included both biliary and pancreatic cancer patients (a feature of many studies of this disease) but the benefits of treatment were seen in both tumour types. 5-Fluorouracil is the most commonly used single agent, with response rates of about 10–20%. Combination of cisplatin and 5-fluorouracil increased the response rate to 32%,64 and further addition of epirubicin (the ECF regimen) produced a 40% response rate and a 40% 1-year survival.65 An interesting agent in this disease is alpha-interferon. A regimen combining a 5-day infusion of 5-fluorouracil with alpha-interferon on Days 1, 3 and 5, repeated every 2 weeks produced a response rate of 39%, and a median survival of 1 year among 19 patients.66
Effectiveness of direct-acting antiviral drugs against hepatitis C virus: predictive factors of response to the treatment
Published in Libyan Journal of Medicine, 2021
María E. Cárdaba-García, Encarnación Abad-Lecha, Miguel Á. Calleja-Hernández
A single-center, observational, retrospective study was carried out. All patients over age 18 diagnosed with cHCV who began treatment against HCV in the Clinical University Hospital of Valladolid, with regimens that incorporated DAAs (DCV, DSV, SOF, LDV, SMV, OMV, PTV) between August 1st, 2014, and February 28th, 2017, were included in the study. If any of these patients did not reach the therapeutic objective and was treated with a different regimen that incorporated DAAs, the new scenario was studied as if it were a new patient. Those patients who received DAAs in combination with alpha-interferon were excluded.
Fixed duration vs. prolonged duration treatment after first line therapy in patients with systemic light chain amyloidosis
Published in Amyloid, 2022
Alfonso Rivera Duarte, Donna Reece, Xuan Li, Wei Xu, Harminder Paul, Esther Masih-Khan, Andrew Winter, Rodger Tiedemann, Anca Prica, Christine Chen, Suzanne Trudel, Vishal Kukreti
Another strategy was explored in phase 2 clinical trial that administered consolidation with bortezomib and dexamethasone for six cycles after ASCT for those patients that did not achieve a hematological CR. In this study, Landau et al. found that hematological response improved in 86% of patients and 55% had evidence of organ improvement as well [22]. Another older prospective study described results with prolonged administration of alpha interferon and dexamethasone as maintenance therapy following an induction phase. However, alpha interferon is no longer used, and toxicity was considerable [23].
Pharmacotherapy for recurrent respiratory papillomatosis (RRP): a treatment update
Published in Expert Opinion on Pharmacotherapy, 2021
The pegylated form of alpha-interferon (peg-interferon alfa-2a, Pegasys®, Roche) is thought to enhance alpha interferons activity [51]. It requires less frequent administration (once weekly) and has fewer side effects [52]. The pegylated form has been used with granulocyte monocyte colony-stimulating factor (GM-CSF) to treat AORRP patients [53]. 9/11 patients who had this treatment administered subcutaneously had no relapse during treatment. This may indicate that the effects of pegylated alpha-interferon deliver enhanced outcomes.